Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
File(s)
Accepted version
Author(s)
Chira, Sergiu
Gulei, Diana
Hajitou, Amin
Berindan-Neagoe, Ioana
Type
Journal Article
Abstract
With an increasing prevalence in the human population, cancer has become one of the most investigated fields of medicine. Among the potential targets for cancer therapy is the tumor suppressor gene TP53, which is found in a mutated state in approximately 50% of human cancers and is often associated with poor prognosis. We propose a novel, highly tumor-specific delivery system for TP53, based on the CRISPR/Cas9 genome editing technology. This system will restore the normal p53 phenotype in tumor cells by replacing the mutant TP53 gene with a functional copy, leading to sustained expression of p53 protein and tumor regression.
Date Issued
2018-07-01
Date Acceptance
2018-01-30
Citation
Trends in Biotechnology, 2018, 36 (7), pp.653-660
ISSN
0167-7799
Publisher
Elsevier
Start Page
653
End Page
660
Journal / Book Title
Trends in Biotechnology
Volume
36
Issue
7
Copyright Statement
© 2018 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/29478674
PII: S0167-7799(18)30048-9
Subjects
AAVP tumor-target vector
CRISPR/Cas9
Cancer
tumor regression
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2018-02-22